Welcome to our dedicated page for Gix Internet news (Ticker: GIXI), a resource for investors and traders seeking the latest updates and insights on Gix Internet stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gix Internet's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gix Internet's position in the market.
Gix Internet (GIXI) launched a new corporate website outlining its strategy for one intelligent, AI-powered management and orchestration layer for robots, people and autonomous systems. The site targets hospitals, potential partners and investors and highlights the current commercial deployment of this platform in hospital logistics via wholly owned subsidiary Deliverz.ai.
Deliverz.ai coordinates autonomous robots and human transport teams for internal deliveries and is designed to integrate with existing hospital infrastructure. At Sheba Medical Center, the system has been in continuous commercial use since December 2025, completing more than 7,000 autonomous missions and cutting chemotherapy delivery time from 40 minutes to 14. Sheba selected Deliverz.ai under a public tender allowing potential deployment of up to 30 robots. Deliverz.ai holds two granted physical-AI navigation patents registered in Israel, Europe and Korea, with further applications under review in the United States and Japan.